Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street Zen

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Sunday.

Other equities analysts have also issued research reports about the company. Wedbush reissued an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, April 16th. Citigroup began coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price on the stock. Finally, Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $39.33.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ:KNSA traded up $1.59 during mid-day trading on Friday, hitting $28.80. The company had a trading volume of 908,924 shares, compared to its average volume of 557,496. Kiniksa Pharmaceuticals International has a fifty-two week low of $17.82 and a fifty-two week high of $30.69. The business's fifty day moving average is $27.69 and its two-hundred day moving average is $23.04. The firm has a market cap of $2.10 billion, a P/E ratio of -115.20 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The firm had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. During the same quarter in the prior year, the firm posted ($0.25) earnings per share. The company's quarterly revenue was up 72.5% on a year-over-year basis. Equities analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, insider Ross Moat sold 27,594 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total value of $800,777.88. Following the sale, the insider owned 9,415 shares of the company's stock, valued at approximately $273,223.30. This trade represents a 74.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mark Ragosa sold 18,299 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $28.80, for a total value of $527,011.20. Following the completion of the sale, the chief financial officer directly owned 27,009 shares in the company, valued at approximately $777,859.20. This represents a 40.39% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 440,863 shares of company stock valued at $12,101,029 over the last 90 days. Insiders own 53.48% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Pallas Capital Advisors LLC acquired a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter valued at approximately $236,000. Voya Investment Management LLC raised its position in Kiniksa Pharmaceuticals International by 54.4% in the 1st quarter. Voya Investment Management LLC now owns 30,866 shares of the company's stock valued at $686,000 after buying an additional 10,878 shares during the last quarter. Rhumbline Advisers raised its position in Kiniksa Pharmaceuticals International by 6.4% in the 1st quarter. Rhumbline Advisers now owns 62,700 shares of the company's stock valued at $1,393,000 after buying an additional 3,745 shares during the last quarter. Strs Ohio acquired a new stake in Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $595,000. Finally, Acadian Asset Management LLC raised its position in Kiniksa Pharmaceuticals International by 170.3% in the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock valued at $22,961,000 after buying an additional 651,700 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.